drugset / Trial / NCT02249065

Mirvaso in Use Study

NCT02249065

Phase 4 Completed 205 enrolled Galderma R&D
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to: 1. assess the signs and symptoms of rosacea, including erythema, without treatment and during treatment with Mirvaso® gel 2. further characterize lifestyle impact and patient satisfaction with Mirvaso® treatment 3. gain a better understanding of the real-world use of Mirvaso® on the pattern and management of facial erythema of rosacea.

Timeline

Start
2014-09
Primary completion
2015-08
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.33 % Topical

Indications